Pharmaceutical patents | Intellepedia

Patents, Compulsory Licensing and Business Strategy

This article explores compulsory licensing in patents under Indian law, focusing on its impact on business strategies and public interest. Through case studies and legal analysis, the article highlights the importance of aligning patent management with India’s unique legal framework.

Gilead, IPA, Natco & The Bells of Harmony

The post examines the collaboration between Gilead, IPA, and Natco Pharma regarding the sofosbuvir patent in India. It analyses how voluntary licensing and innovative policies are improving access to affordable medicines while balancing public health and patent rights.

Pfizer files for Patent on Known Substance

This post examines Pfizer’s patent application on a known substance and the Indian Patent Office’s refusal in light of Section 3d and the Novartis decision. It discusses whether unpublished patent applications can render a substance as “known” and critiques the merging of novelty and subject matter analysis.

Pfizer falls prey to Section 3(d)

This post analyses the Indian Patent Office’s rejection of Pfizer’s Tofacitinib patent under Section 3(d). The decision addresses issues of novelty, inventive step, and the requirement for evidence of enhanced efficacy in pharmaceutical patent applications.

Lee Pharma v. AstraZeneca- An unfinished Patent Story

This post examines the Lee Pharma v. AstraZeneca case on compulsory licensing under Indian patent law. The Controller’s decision sheds light on the standards for proving public need, affordable pricing, and working of patents in India.

Intellectual Property (IP) in India: A Decade of Progress Part 11

This post presents a statistical overview of pharmaceutical patents in India over the past decade, focusing on trends and key contributors. It objectively discusses the impact of legal changes and regulatory measures on patent filings in the pharmaceutical sector.

Roche loses again

The Indian Patent Office has revoked Roche’s Valganciclovir patent, emphasizing Section 3d and public interest. This decision strengthens access to medicines in India and curbs evergreening by pharmaceutical companies.

Patent Infringement Claim on Cancer Treatment Drug

The UK Court of Appeal ruled that Actavis’s alternative salt forms of pemetrexed would indirectly infringe Eli Lilly’s cancer drug patent. The decision provides insights into patent claim construction and the approach to pharmaceutical patent disputes across multiple European jurisdictions.

‘Killead’s Patent Application Killed by the Indian Patent Office!

Gilead’s patent for Sofosbuvir was rejected by the Indian Patent Office on grounds of insufficient therapeutic efficacy. This landmark decision enables wider access to affordable generic Hepatitis C treatments in India.

Roche’s backbone rendered brittle by Indian Patent Office

The Indian Patent Office has revoked Roche’s patent on Bonviva after Cipla challenged its validity, citing a lack of inventive step and patentability. This decision highlights critical aspects of Indian pharmaceutical patent law and its impact on international drug companies.